Overview

Neoadjuvant FOLFIRINOX or Nab-paclitaxel With Gemcitabine for Borderline Resectable Pancreatic Cancer

Status:
Active, not recruiting

Trial end date:
2023-06-01

Target enrollment:

Participant gender:

Summary

The aim of this study is to clarify the efficacy and safety of neoadjuvant FOLFIRINOX and nab-paclitaxel + gemcitabine for borderline resectable pancreatic cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Nagoya University

Treatments:

Albumin-Bound Paclitaxel
Folfirinox
Gemcitabine
Paclitaxel